Twigg Stephen M, Kamp Maarten C, Davis Timothy M, Neylon Elizabeth K, Flack Jeffrey R
Department of Medicine, University of Sydney, Sydney, NSW, Australia.
Med J Aust. 2007 May 7;186(9):461-5. doi: 10.5694/j.1326-5377.2007.tb00998.x.
Prediabetes, the presence of impaired fasting glucose/glycaemia and/or impaired glucose tolerance, affects about 16.4% of Australian adults. People with prediabetes are at increased risk of developing diabetes, and cardiovascular and other macrovascular disease. Management includes reducing cardiovascular disease risk factors, specifically lipid and blood pressure abnormalities, and smoking-cessation counselling. To help prevent progression to diabetes, people with prediabetes who are overweight or obese require intensive lifestyle intervention. Medication to help prevent diabetes may also be used, but only after a minimum of 6 months of lifestyle intervention. In people with prediabetes, there is no role for routinely testing: capillary blood glucose; glycated haemoglobin (HbA(1c)) levels; serum insulin or pancreatic C-peptide levels; or testing for ischaemic heart disease or the microvascular complications of diabetes. Follow-up assessment of glycaemia in prediabetes requires a formal 75 g oral glucose tolerance test, initially performed annually, with subsequent individualised testing frequency.
糖尿病前期,即空腹血糖/血糖受损和/或糖耐量受损,影响着约16.4%的澳大利亚成年人。糖尿病前期患者患糖尿病、心血管疾病和其他大血管疾病的风险增加。管理措施包括降低心血管疾病风险因素,特别是血脂和血压异常,以及戒烟咨询。为帮助预防进展为糖尿病,超重或肥胖的糖尿病前期患者需要强化生活方式干预。也可使用有助于预防糖尿病的药物,但至少要在生活方式干预6个月后使用。对于糖尿病前期患者,常规检测毛细血管血糖、糖化血红蛋白(HbA(1c))水平、血清胰岛素或胰岛C肽水平,或检测缺血性心脏病或糖尿病微血管并发症均无意义。糖尿病前期血糖的随访评估需要进行正式的75克口服葡萄糖耐量试验,最初每年进行一次,随后根据个体情况确定检测频率。